BIOGEN IDEC - Diversification and Strong Foothold in MS to Reign
We continue to like Biogen Idec (BIIB) as next year is also going to be eventful: Approval and launch of BG-12 (dimethyl fumerate, under review with FDA & EMEA, est. PDUFA: late Mar. 2013, peak sales potential ww – $2.5b by 2018) and clinical news flow from its late stage pipeline products. BIIB revised its FY12 sales growth guidance upwards (from mid-single digits to mid to high-single digits) on growing volumes despite growing competition in the MS therapy area. For more details on the upcoming catalysts, please read our report released on 7th Nov. 2012, titled, “Biogen Idec - Diversification and Strong Foothold in MS to Reign”.
More Publications
Biogen Idec business profile (company report)
US$ 99.00
August 2011
30 pages
BIOGEN IDEC - Data of BG-12 + Sales Growth Brighten 2012 Prospects
US$ 140.00
November 2011
6 pages
BIOGEN IDEC - Investing for Long-Term
US$ 140.00
February 2012
9 pages
